Asthma  >>  Synacthen Depot (cosyntropin)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Synacthen Depot (cosyntropin) / Novartis, Mallinckrodt, Alliance
2012-003241-15: A study to develop a non-invasive version of the diagnostic test of the body's ability to produce enough stress hormone.

Not yet recruiting
1
258
Europe
100mcg tetracosactide (in a 1:1 mix with chitosan), 500 mcg tetracosactide, 500 mcg tetracosactide (in a mix 1:1 with chitosan), 1 mcg Synacthen, Nasal spray, solution, Suspension for injection, Synacthen
Sheffield Children's NHS Foundation Trust
In stages 1+2 of the study healthy volunteers will be used to determine the bioequivalence of nasal Synacthen with 1 microgram of intravenous synacthen. Stage 3 will use healthy children to establish normal ranges for the adrenal response to a low-dose synacthen test. In stage 4 adrenal function in asthmatic individuals on inhaled corticosteroids will be studied., Inability to produce the stress hormone, cortisol, is known as adrenal insufficiency. It can cause serious illness and even death. Inhaled steroids taken for asthma can cause adrenal insufficiency., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
 
 

Download Options